Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, gives an update on a Phase I trial (NCT02924402) of plamotamab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The study reported a manageable toxicity profile, and a benefit with plamotamab in this heavily pre-treated patient group with respect to overall response (OR) and complete response (CR) rates. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.